The term “340B” is widely used across healthcare, pharmacy, and compliance conversations — yet it is often misunderstood. Many professionals interact with 340B programs daily without fully understanding what 340B actually refers to, where it came from, or why it plays such a critical role in supporting safety-net healthcare.
At its core, 340B refers to a federal drug pricing program designed to help eligible healthcare organizations stretch scarce resources, expand patient access, and support care for underserved populations. Over time, the program has grown significantly in size, complexity, and scrutiny, making a clear understanding of its purpose and structure more important than ever.
This article explains what 340B refers to, how the program works, who it applies to, and why it remains a cornerstone of healthcare delivery for vulnerable communities.
Want to better understand how 340B applies to your organization?
Contact Cooper Strategy
What the Term “340B” Actually Refers To
The Origin of the Name
“340B” refers to Section 340B of the Public Health Service Act. This section of federal law established the 340B Drug Pricing Program, requiring pharmaceutical manufacturers to provide outpatient drugs at significantly reduced prices to eligible healthcare organizations, known as covered entities.
The name does not describe a discount level, rebate, or funding source — it refers specifically to the statutory section that created the program.
What the Program Is Designed to Do
The intent of 340B is to allow eligible organizations to:
- Stretch limited federal resources
- Expand access to care
- Support services for vulnerable and underserved patients
- Offset uncompensated care and underfunded services
The program is not a grant and does not provide direct funding. Instead, it reduces drug acquisition costs, allowing organizations to redirect savings into patient care.
How the 340B Program Works
Manufacturer Participation
Drug manufacturers that want their products covered under Medicaid or Medicare Part B are required to participate in the 340B program. Participation requires manufacturers to sell covered outpatient drugs to eligible entities at discounted prices.
These discounts are not optional for participating manufacturers.
Covered Entities
Only organizations that meet specific statutory criteria may participate. These entities include certain hospitals and federally funded clinics that serve a disproportionate share of low-income or underserved patients.
Eligibility is tightly defined and monitored.
Outpatient Drug Focus
The 340B program applies only to outpatient drugs. Drugs administered to inpatients are not eligible for 340B pricing. This outpatient limitation is central to compliance and is a major focus of audits.
Who Benefits From the 340B Program
Patients
Patients benefit indirectly through:
- Expanded service offerings
- Improved access to medications
- Enhanced specialty care availability
- Support services that might otherwise be unavailable
The program is designed to strengthen the healthcare safety net.
Covered Entities
Covered entities benefit by:
- Reducing drug acquisition costs
- Offsetting under-reimbursed care
- Supporting high-cost service lines
- Investing in care coordination and access initiatives
Savings may be used flexibly to meet community needs.
Communities
Communities benefit when safety-net providers remain financially stable and able to offer comprehensive services, especially in rural or underserved areas.
Common Misunderstandings About What 340B Refers To
340B Is Not a Reimbursement Program
340B does not reimburse providers or pharmacies. It reduces the cost at which eligible drugs are purchased.
340B Is Not a Grant
There is no direct funding associated with 340B. Savings are generated through reduced drug prices.
340B Is Not Limited to Medicaid Patients
Eligibility is based on the patient relationship and outpatient status — not insurance type. Commercially insured, Medicare, and uninsured patients may all qualify if eligibility criteria are met.
340B Is Not Automatic
Participation requires registration, ongoing recertification, compliance controls, and continuous oversight.
How 340B Interacts With Pharmacies
In-House Pharmacies
Covered entities with in-house pharmacies may dispense 340B drugs directly to eligible patients, using replenishment models to manage inventory.
Contract Pharmacies
Covered entities may contract with external pharmacies to dispense drugs on their behalf. Contract pharmacy arrangements significantly expanded access but also increased complexity and scrutiny.
Oversight Responsibility
Regardless of pharmacy arrangement, the covered entity retains full responsibility for compliance.
Why 340B Is Increasingly Scrutinized
Program Growth
The 340B program has grown substantially, particularly through:
- Hospital participation
- Contract pharmacy expansion
- Specialty drug utilization
Growth has attracted increased oversight.
Manufacturer Concerns
Manufacturers closely monitor eligibility, referral capture, and contract pharmacy activity, often through audits.
Regulatory Expectations
Regulators expect covered entities to demonstrate compliance through documentation, data integrity, and governance.
The Operational Reality of 340B Today
Data-Driven Compliance
Modern 340B programs depend on:
- Accurate eligibility logic
- System integration
- Documentation standards
- Continuous auditing
Manual approaches are no longer sufficient.
Governance and Accountability
Strong governance structures are essential to manage risk and sustain program value.
Strategic Importance
For many organizations, 340B supports critical service lines such as oncology, infectious disease, behavioral health, and rural access care.
Cooper Strategy helps organizations translate the intent of 340B into compliant, sustainable operations.
Contact us to learn more
Conclusion
So, what does 340B refer to? It refers to a federal statute designed to strengthen the healthcare safety net by reducing outpatient drug costs for eligible organizations. While the concept is simple, the operational reality is complex and highly regulated.
Organizations that understand the purpose, structure, and requirements of 340B are better positioned to protect compliance, maximize program value, and continue serving vulnerable communities.
Frequently Asked Questions About What Does 340B Refer To?
Why is the program called “340B” instead of something more descriptive?
The program is named after Section 340B of the Public Health Service Act, which established the drug pricing requirements. The name reflects its statutory origin rather than its function. While not descriptive on its own, “340B” has become shorthand across healthcare for the drug pricing program and its associated compliance framework.
Does 340B provide free drugs to hospitals or clinics?
No. The 340B program provides discounted pricing, not free drugs. Covered entities must still purchase medications, but at significantly reduced prices. The savings generated help organizations support patient care, expand services, and offset uncompensated or underfunded care.
Do all patients of a covered entity qualify for 340B?
No. Eligibility is determined at the encounter level based on patient definition criteria, outpatient status, and responsibility for care. Insurance type alone does not determine eligibility. Each prescription or administration must be evaluated individually.
Why is 340B compliance so complex?
Compliance is complex because it involves multiple systems, providers, locations, pharmacies, and regulatory requirements. Eligibility, documentation, duplicate discount prevention, and audit readiness must all align. Small gaps can create significant risk, especially in large or specialty-driven programs.
How can Cooper Strategy help organizations understand and manage 340B?
Cooper Strategy helps organizations understand what 340B refers to in practical terms by translating statutory intent into operational workflows. We assess compliance, optimize eligibility and referral capture, strengthen governance, and help organizations sustain the value of their 340B programs while remaining audit-ready.